The BioHub - by Avetix Episode 105 - Ahmet Tutuncu - CEO of AeroRx Therapeutics
7 snips
Jan 15, 2026 
Ahmet Tutuncu, a physician-scientist and CEO of AeroRx Therapeutics, shares his insights on innovative nebulized therapies for COPD. He discusses the development of AERO-007, the first nebulized LABA/LAMA duo, and AERO-111, a groundbreaking triple therapy. The conversation highlights the unique challenges of targeting older COPD patients who struggle with inhalers. Ahmet also explores the renewed investor interest in nebulized solutions following major deals in the industry, reflecting on the mission to improve patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Longstanding Respiratory Biotech Career
- Ahmet trained and practiced medicine in Turkey, earned a PhD in respiratory pathophysiology, and joined the San Diego biotech community nearly 30 years ago.
- He co-founded two inhaled-drug companies that were acquired and now co-founded AeroRx to develop a dual nebulized bronchodilator for COPD.
Unmet Nebulized Dual Therapy Gap
- The COPD treatment paradigm shifted from single to dual bronchodilators over the past decade, leaving a nebulized gap.
- AeroRx aims to fill that unmet need by formulating a dual bronchodilator for nebulized delivery.
Why Nebulizers Suit Severe COPD
- Older, sicker COPD patients often cannot effectively use handheld inhalers due to coordination and effort requirements.
- Nebulizers deliver full doses via effortless tidal breathing and offer rapid, reliable relief for these patients.